Literature DB >> 3822285

Clinical patterns of tumor recurrence after radical hysterectomy in stage IB cervical carcinoma.

T W Burke, W J Hoskins, P B Heller, M C Shen, E B Weiser, R C Park.   

Abstract

We reviewed the cases of 31 patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB cervical carcinoma who developed recurrent disease after radical hysterectomy and pelvic lymphadenectomy between 1961 and 1982. The overall incidence of recurrence was 11.3%. Recurrence was significantly more common in patients with adenocarcinoma or adenosquamous carcinoma (17.4%) than in those with pure squamous tumors (9.2%). The median time from operation to recurrence was eight months. The median survival of patients dying of disease was 18 months. Sites of recurrence were categorized as central pelvic in 35% of cases, pelvic sidewall in 39%, and distant in 26%. Patients treated with postoperative pelvic radiotherapy for positive pelvic nodes or surgical margin involvement were more likely to develop distant recurrence. Various therapeutic modalities were used to treat recurrent disease. Twenty-two of 23 patients with central pelvic or sidewall recurrence failed radiation therapy. None of four patients with central recurrence treated by pelvic exenteration survived. No patient treated with chemotherapy survived. Overall survival for patients with recurrence was 3.2%. The dismal prognosis for this group of patients warrants evaluation of alternative treatment modalities.

Entities:  

Mesh:

Year:  1987        PMID: 3822285

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

1.  Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer.

Authors:  Sang-Won Kim; Mison Chun; Hee-Sug Ryu; Suk-Joon Chang; Tae Wook Kong; Eun Ju Lee; Yong Hee Lee; Young-Taek Oh
Journal:  Strahlenther Onkol       Date:  2017-03-29       Impact factor: 3.621

2.  [Pelvic wall recurrence of cervix carcinomas. Combined surgical-radio-chemotherapeutic procedure (CORCT)].

Authors:  R Schulz-Wendtland; S Krämer; M Säbel; F Heller; L Keilholz; W Jäger; R Sauer; N Lang; W Bautz
Journal:  Strahlenther Onkol       Date:  1998-05       Impact factor: 3.621

3.  Phosphorylated c-Src is a novel predictor for recurrence in cervical squamous cell cancer patients.

Authors:  Teng Hou; Juan Xiao; Huiting Zhang; Haifeng Gu; Yanling Feng; Jundong Li
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

4.  Recurrent uterine cancer after surgery: magnetic resonance imaging patterns and their changes after concomitant chemoradiation.

Authors:  R Manfredi; S Baltieri; A Tognolini; R Graziani; D Smaniotto; N Cellini; L Bonomo
Journal:  Radiol Med       Date:  2008-09-08       Impact factor: 3.469

5.  Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer.

Authors:  Tzu-Chen Yen; Chyong-Huey Lai; Shih-Ya Ma; Kuan-Gen Huang; Huei-Jean Huang; Ji-Hong Hong; Swei Hsueh; Wuu-Jyh Lin; Koon-Kwan Ng; Ting-Chang Chang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-18       Impact factor: 10.057

6.  Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix.

Authors:  Q Cheng; W M Lau; S H Chew; T H Ho; S K Tay; K M Hui
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

7.  HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.

Authors:  Mariette I E van Poelgeest; Marij J P Welters; Edith M G van Esch; Linda F M Stynenbosch; Gijs Kerpershoek; Els L van Persijn van Meerten; Muriel van den Hende; Margriet J G Löwik; Dorien M A Berends-van der Meer; Lorraine M Fathers; A Rob P M Valentijn; Jaap Oostendorp; Gert Jan Fleuren; Cornelis J M Melief; Gemma G Kenter; Sjoerd H van der Burg
Journal:  J Transl Med       Date:  2013-04-04       Impact factor: 5.531

8.  Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer.

Authors:  Mariëtte I E van Poelgeest; Valeria V Visconti; Zohara Aghai; Vanessa J van Ham; Moniek Heusinkveld; Maarten L Zandvliet; A Rob P M Valentijn; Renske Goedemans; Caroline E van der Minne; Els M E Verdegaal; J Baptist M Z Trimbos; Sjoerd H van der Burg; Marij J P Welters
Journal:  Cancer Immunol Immunother       Date:  2016-09-12       Impact factor: 6.968

9.  Pattern of Failure with Locally Advanced Cervical Cancer– A Retrospective Audit and Analysis of Contributory Factors

Authors:  Anis Bandyopadhyay; Upasana Mukherjee; Sandip Ghosh; Saurav Ghosh; Shyamal Kumar Sarkar
Journal:  Asian Pac J Cancer Prev       Date:  2018-01-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.